Sunshine Biopharma, Inc.
SBFM
$2.18
$0.041.87%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -20.07% | -16.38% | -41.81% | -71.39% | -23.06% |
| Total Depreciation and Amortization | 40.09% | 48.59% | 49.08% | 54.42% | 56.40% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -- | 14,554.17% | 12,936.29% | 8,748.33% | -100.00% |
| Change in Net Operating Assets | 71.96% | 81.28% | 61.21% | 62.88% | -0.94% |
| Cash from Operations | 48.44% | 57.59% | 39.87% | 29.14% | -9.14% |
| Capital Expenditure | 89.25% | 89.47% | 76.27% | -18.43% | -1,003.79% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -850.25% | -116.51% | 33.38% | 14.00% | 107.64% |
| Cash from Investing | 49.77% | 55.93% | 57.23% | -0.75% | -29.20% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -42.23% | -- | 151.98% | 99.83% | 123.83% |
| Issuance of Common Stock | 13.54% | -60.70% | -46.09% | -12.04% | -69.44% |
| Repurchase of Common Stock | -- | -- | 100.00% | 100.00% | 100.00% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 13.12% | -46.70% | -22.40% | 42.88% | -58.36% |
| Foreign Exchange rate Adjustments | 227.83% | 182.03% | -2,049.64% | 141.07% | -1,077.63% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 86.99% | 91.47% | 56.32% | 85.38% | -400.52% |